Fidia Complete logo

This convenient program includes insurance benefit investigation and prior authorization support, and timely status updates.

Complete support for your office to prescribe HYMOVIS® ONE with confidence

Hymovis One prefilled syringe and packaging box
Hymovis One logo

Quick turnaround (48 hours or less)

Patient-specific benefits investigation

Prior authorization applications and support renewals

Appeals assistance

Specialty pharmacy triage

Real-time enrollment status updates

Allows for maximized visibility and the insight necessary to track a referral’s journey throughout the fulfillment process.

Support hotline
 1-866-749-2542, Option 2

Available Monday-Friday, 9 AM to 8 PM ET

Fax: 1-877-447-9734


For patient insurance verification, register/login to: www.fidiacomplete.com

Access necessary resources for reimbursement

HYMOVIS® ONE Reimbursement Guide.pdf

HYMOVIS® ONE Letter Medical of Necessity.pdf
HYMOVIS® ONE Patient Enrollment Form.pdf
HYMOVIS® ONE Sample Letter of Appeal.pdf
HYMOVIS® ONE Prior Authorization Checklist.pdf
Fidia Complete Information Sheet

Indication

HYMOVIS® ONE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics (e.g., acetaminophen).

Important Safety Information

HYMOVIS® ONE is contraindicated in patients with known hypersensitivity (allergy) to hyaluronate preparations or gram-positive bacterial proteins. Do not administer HYMOVIS® ONE to patients with infections or skin diseases in the area of the injection site or joint. The safety and effectiveness of HYMOVIS® ONE has not been established in pregnant women, nursing mothers, or children or for use in joints other than the knee, or concomitant use with other intra-articular (IA) injections. The effectiveness of repeat treatment cycles of HYMOVIS® ONE has not been established. No serious adverse events or pseudoseptic reactions were reported in the HYMOVIS® ONE clinical study. The adverse events experienced and reported in the HYMOVIS® ONE clinical study were joint swelling, metatarsalgia, neck pain and headache.

Rx Only. See package insert for full prescribing information including indications, contraindications, adverse events, warnings, precautions, and side effects.

About
Hymovis® One

Scientific Evidence

CLINICAL SAFETY AND EFFICACY

Patients Resources

HOW TO Order

You are about to leave this website

External content may be subject to different local regulations, product availability may vary by market.

THIS PAGE IS INTENDED ONLY FOR HEALTHCARE PROFESSIONALS

To access this page, please click YES if you are a healthcare professional.
If you are not a healthcare professional, select NO.